Congenital Chagas Disease in the United States: Cost Savings through Maternal Screening
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Congenital Chagas Disease in the United States: Cost Savings through Maternal Screening

Filetype[PDF-412.79 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      Am J Trop Med Hyg
    • Publisher's site:
      http://dx.doi.org/10.4269/ajtmh.17-0818
    • Personal Author:
    • Description:
      Chagas disease, caused by |, is transmitted by insect vectors through transfusions, transplants, insect feces in food, and from mother to child during gestation. Congenital infection could perpetuate Chagas disease indefinitely, even in countries without vector transmission. An estimated 30% of infected persons will develop lifelong, potentially fatal, cardiac or digestive complications. Treatment of infants with benznidazole is highly efficacious in eliminating infection. This work evaluates the costs of maternal screening and infant testing and treatment of Chagas disease in the United States. We constructed a decision-analytic model to find the lower cost option, comparing costs of testing and treatment, as needed, for mothers and infants with the lifetime societal costs without testing and the consequent morbidity and mortality due to lack of treatment or late treatment. We found that maternal screening, infant testing, and treatment of Chagas disease in the United States are cost saving for all rates of congenital transmission greater than 0.001% and all levels of maternal prevalence above 0.06% compared with no screening program. Newly approved diagnostics make universal screening cost saving with maternal prevalence as low as 0.008%. The present value of lifetime societal savings due to screening and treatment is about $634 million saved for every birth year cohort. The benefits of universal screening for | as part of routine prenatal testing far outweigh the program costs for all U.S. births.
    • Subject:
    • Source:
      Am J Trop Med Hyg. 2018; 98(6):1733-1742.
    • Pubmed ID:
      29714163
    • Pubmed Central ID:
      PMC6086189
    • Document Type:
      Journal Article
    • Collection(s):
      CDC Public Access
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov